NASDAQ · STOCK
Boston Scientific
$44.77
52W $42.25 – $109.50
64/100
$67.47B
18.9
0.58
Price History (6M)
⚠
Buy rating, but near-term risk/reward is unfavorable
The long-term recommendation is based on the composite investment score. The near-term risk/reward is based on nearby support and resistance levels. These can differ when a strong company trades close to resistance with support further below.
Executive Summary
6 analysts weighed in with 67% agreement on a bullish lean. Portfolio Manager: Portfolio position concentration is currently healthy. Overall recommendation: BUY.
Bull & Bear Case
Bull Case
- Positive MACD histogram signals bullish momentum.
- Daily volatility (ATR%) above ~3% is treated as elevated risk.
Bear Case
- Daily trend is down — entering long positions against the trend.
- Both daily and weekly trends are bearish — strong multi-timeframe downtrend.
- Lower Highs / Lower Lows structure confirms bearish price action.
AI Investment Committee
Committee Consensus
As of July 11, 2026
Overall Committee Score
64/100
Agreement
60%
Analysts
5
Conviction
Moderate
Value Analyst
neutral
53
/ 100 · Moderate confidence
Fair value -- neither a bargain nor obviously overpriced
− Price-to-book of 5.8x prices in significant intangible value
Growth Analyst
bullish
66
/ 100 · High confidence
Strong, accelerating growth with consistent execution
+ EPS growing 74.7% YoY
− Growth rate is decelerating quarter over quarter -- the trend line matters more than the level
Technical Analyst
neutral
56
/ 100 · High confidence
Mixed or range-bound price action
+ MACD histogram positive -- bullish momentum
− Price structure making lower highs and lower lows
Macro Analyst
bullish
70
/ 100 · Moderate confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
+ Market regime is bullish (Bull market -- normal position sizing)
News Analyst
bullish
62
/ 100 · Low confidence
News flow and recent filings/analyst actions are net positive
Portfolio Manager
bullish
75
/ 100 · Low confidence
The existing book is healthy enough that position-sizing here is a matter of stock selection, not portfolio constraints
+ Portfolio position concentration is currently healthy
Technical Analysis
RSI (14)
47.4
Neutral
MACD Histogram
0.478
Bullish Momentum
Trend Direction
Downtrend
Weekly: Downtrend
Market Structure
Lh Ll
Support
$44.35
Resistance
$45.17
Bollinger %B
0.46
Inside Bands
Price vs Moving Averages
EMA 9
$44.71
Above
EMA 21
$45.72
Below
EMA 50
$50.35
Below
EMA 200
$70.65
Below
Fundamental Analysis
Valuation
59
Growth
81
Profitability
86
Financial Health
84
Valuation
P/E Ratio
18.9×
P/B Ratio
5.83×
PEG Ratio
—
Dividend Yield
—
52W High
$109.50
52W Low
$42.25
Quality & Growth
ROE
1487.0%
ROA
828.0%
Gross Margin
6914.0%
Operating Margin
1840.0%
Revenue Growth YoY
+1744.0%
Debt / Equity
0.47
AI Fundamental Assessment
P/E ratio of 18.9 (inexpensive relative to a 15-40x range); Price-to-book of 5.8x; Revenue growth (YoY) of 17.4%; EPS growth (YoY) of 74.7%; Return on equity of 14.9%; Return on assets of 8.3%; Net margin of 17.3%; Gross margin of 69.1%; Current ratio of 1.62 (healthy short-term liquidity); Debt-to-equity of 0.47; Most recent quarter beat estimates by 0.7%; 4 consecutive earnings beats; EPS growth decelerating (+6.7% -> +0.0% QoQ); Analyst estimates rising over recent quarters
Key Risks
- Daily trend is down — entering long positions against the trend.
- Both daily and weekly trends are bearish — strong multi-timeframe downtrend.
- Lower Highs / Lower Lows structure confirms bearish price action.
This risk summary is generated from quantitative data signals, not qualitative opinion. All investors should conduct their own due diligence. This is not financial advice.
Get the Full BSX Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →
Mobile